CA2947429A1 - Humanized variable lymphocyte receptors (vlr) and compositions and uses related thereto - Google Patents

Humanized variable lymphocyte receptors (vlr) and compositions and uses related thereto Download PDF

Info

Publication number
CA2947429A1
CA2947429A1 CA2947429A CA2947429A CA2947429A1 CA 2947429 A1 CA2947429 A1 CA 2947429A1 CA 2947429 A CA2947429 A CA 2947429A CA 2947429 A CA2947429 A CA 2947429A CA 2947429 A1 CA2947429 A1 CA 2947429A1
Authority
CA
Canada
Prior art keywords
amino acid
certain embodiments
seq
acid sequence
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2947429A
Other languages
English (en)
French (fr)
Inventor
Brantley R. Herrin
Max Dale COOPER
Rudolf EHRHARDT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of CA2947429A1 publication Critical patent/CA2947429A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2947429A 2014-05-02 2015-04-30 Humanized variable lymphocyte receptors (vlr) and compositions and uses related thereto Abandoned CA2947429A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461987566P 2014-05-02 2014-05-02
US61/987,566 2014-05-02
PCT/US2015/028645 WO2015168469A1 (en) 2014-05-02 2015-04-30 Humanized variable lymphocyte receptors (vlr) and compositions and uses related thereto

Publications (1)

Publication Number Publication Date
CA2947429A1 true CA2947429A1 (en) 2015-11-05

Family

ID=54359347

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2947429A Abandoned CA2947429A1 (en) 2014-05-02 2015-04-30 Humanized variable lymphocyte receptors (vlr) and compositions and uses related thereto

Country Status (8)

Country Link
US (3) US10167330B2 (enExample)
EP (1) EP3137496A4 (enExample)
JP (1) JP2017514522A (enExample)
KR (1) KR20160147787A (enExample)
CN (1) CN106459173A (enExample)
CA (1) CA2947429A1 (enExample)
IL (1) IL248327A0 (enExample)
WO (1) WO2015168469A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017514522A (ja) 2014-05-02 2017-06-08 エモリー ユニバーシティー ヒト化可変性リンパ球受容体（ｖｌｒ）および組成物ならびにそれに関連する使用
SE1500434A1 (en) * 2015-10-29 2017-04-30 Theravac Pharmaceuticals Ab A novel fusion partner for highly efficient and safe vaccines
CN107365387B (zh) 2016-05-12 2022-03-15 阿思科力(苏州)生物科技有限公司 一种双特异性抗原结合构建体及其制备方法和应用
US11339225B2 (en) * 2016-05-12 2022-05-24 Asclepius (Suzhou) Technology Company Group, Co., Ltd. Bispecific antigen-binding construct and preparation method and use thereof
CN106543278B (zh) * 2016-12-06 2019-04-12 阿思科力(苏州)生物科技有限公司 融合蛋白Slit2D2(C386S)-HSA及其在治疗纤维化疾病中的应用
WO2018140857A2 (en) * 2017-01-27 2018-08-02 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Bifunctional small peptide for autoimmune diabetes
BR112019019973A2 (pt) * 2017-03-24 2020-04-28 Orpheus Bioscience Inc pantlds para tratamento de transtornos autoimunes
MY200973A (en) * 2017-04-11 2024-01-26 Inhibrx Inc Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
KR101972894B1 (ko) * 2017-05-18 2019-04-29 경상대학교산학협력단 소수성 테일 도메인이 제거된 먹장어 유래 vlrb 단백질에 칠성장어 유래 vlrb 단백질의 c 말단 서열이 연결된 융합 단백질 및 이의 용도
TW202010757A (zh) 2018-04-11 2020-03-16 美商英伊布里克斯公司 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途
WO2020023553A1 (en) 2018-07-24 2020-01-30 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
US12590169B2 (en) 2018-10-11 2026-03-31 Inhibrx Biosciences, Inc. 5T4 single domain antibodies and therapeutic compositions thereof
JP7611820B2 (ja) 2018-10-11 2025-01-10 インヒブルクス バイオサイエンシズ インコーポレイテッド Ｄｌｌ３シングルドメイン抗体およびその治療用組成物
WO2020132301A1 (en) * 2018-12-21 2020-06-25 Wisconsin Alumni Research Foundation Variable lymphocyte receptors that target the brain extracellular matrix and methods of use
WO2020167735A1 (en) 2019-02-11 2020-08-20 Wisconsin Alumni Research Foundation Variable lymphocyte receptors that target the blood brain barrier and methods of use
EP4058469A1 (en) * 2019-11-12 2022-09-21 Institut National de la Santé et de la Recherche Médicale (INSERM) New serological marker for the latent form of toxoplasmosis
WO2023010060A2 (en) 2021-07-27 2023-02-02 Novab, Inc. Engineered vlrb antibodies with immune effector functions
CN114891799B (zh) * 2022-05-20 2024-10-11 宁波大学 中华绒螯蟹可变淋巴受体vlr2基因及其编码的蛋白和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1118777A (ja) * 1997-07-09 1999-01-26 Asahi Chem Ind Co Ltd 新規スリット様ポリペプチド
US8039588B2 (en) 2004-05-21 2011-10-18 The Uab Research Foundation Variable lymphocyte receptors
WO2008016854A2 (en) 2006-08-02 2008-02-07 The Uab Research Foundation Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity
US9127087B2 (en) 2008-12-01 2015-09-08 University Of Maryland, Baltimore High affinity recombinant sea lamprey antibodies selected by a Yeast Surface Display platform
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2013078425A1 (en) 2011-11-22 2013-05-30 University Of Maryland, Baltimore Lambodies with high affinity and selectivity for glycans and uses therefor
CN103033617B (zh) * 2012-11-30 2014-12-03 辽宁师范大学 基于可变淋巴细胞受体的肿瘤标志物检测试剂盒及其制备方法
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
JP2017514522A (ja) 2014-05-02 2017-06-08 エモリー ユニバーシティー ヒト化可変性リンパ球受容体（ｖｌｒ）および組成物ならびにそれに関連する使用

Also Published As

Publication number Publication date
US10167330B2 (en) 2019-01-01
US20190202887A1 (en) 2019-07-04
WO2015168469A1 (en) 2015-11-05
KR20160147787A (ko) 2016-12-23
EP3137496A4 (en) 2017-10-11
JP2017514522A (ja) 2017-06-08
US20200308247A1 (en) 2020-10-01
IL248327A0 (en) 2016-11-30
CN106459173A (zh) 2017-02-22
EP3137496A1 (en) 2017-03-08
US11384134B2 (en) 2022-07-12
US20170081385A1 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
US11384134B2 (en) Recombinant vector and expression system comprising a nucleic acid encoding a variable lymphocyte receptor (VLR)
US11136369B2 (en) Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
JP7642010B2 (ja) 改良された抗原結合受容体
US11919970B2 (en) Antibodies and chimeric antigen receptors specific for ROR1
US11827714B2 (en) Antibodies and chimeric antigen receptors specific for CD19
EP4527466A2 (en) Anti-dll3 chimeric antigen receptors and uses thereof
JP6549622B2 (ja) 前立腺特異幹細胞抗原に対する抗体およびその使用
CN110177808A (zh) 针对axl或ror2的嵌合抗原受体及其使用方法
CN111448314B (zh) 根据可开发性选择真核细胞展示系统中的多肽药物
WO2020232447A1 (en) Lockr-mediated recruitment of car t cells
CN111492243A (zh) 用于新颖抗原结合模块的特异性测试的car-t细胞测定法
US20240158500A1 (en) CD160 Binding Domain
EP4341702A2 (en) Structure based isolation of pmhc-restricted antibodies
WO2025059589A1 (en) Immune cell engaging molecules
KR20250143301A (ko) 항-넥틴4 키메라 항원 수용체를 갖는 유전자 조작 세포 및 이의 용도
HK40117019A (en) Claudin-6 binding moieties and uses thereof
WO2024231348A1 (en) Slc4a4/nbce1 inhibitors
HK40049993A (en) Antibodies and chimeric antigen receptors specific for cd19
HK40019803B (en) Improved antigen binding receptors
HK1240239B (en) Antibodies and chimeric antigen receptors specific for cd19
HK1240239A1 (en) Antibodies and chimeric antigen receptors specific for cd19
HK1197419A (en) Antibodies against prostate-specific stem cell antigen and use thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200424

FZDE Discontinued

Effective date: 20220823